Literature DB >> 25432175

Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer.

J Jacob Wamsley1, Manish Kumar1, David F Allison1, Sheena H Clift1, Caitlyn M Holzknecht1, Szymon J Szymura1, Stephen A Hoang1, Xiaojiang Xu1, Christopher A Moskaluk2, David R Jones3, Stefan Bekiranov1, Marty W Mayo4.   

Abstract

Soluble growth factors and cytokines within the tumor microenvironment aid in the induction of the epithelial-to-mesenchymal transition (EMT). Although EMT promotes the development of cancer-initiating cells (CIC), cellular mechanisms by which cancer cells maintain mesenchymal phenotypes remain poorly understood. Work presented here indicates that induction of EMT stimulates non-small cell lung cancer (NSCLC) to secrete soluble factors that function in an autocrine fashion. Using gene expression profiling of all annotated and predicted secreted gene products, we find that NF-κB activity is required to upregulate INHBA/Activin, a morphogen in the TGFβ superfamily. INHBA is capable of inducing and maintaining mesenchymal phenotypes, including the expression of EMT master-switch regulators and self-renewal factors that sustain CIC phenotypes and promote lung metastasis. Our work demonstrates that INHBA mRNA and protein expression are commonly elevated in primary human NSCLC and provide evidence that INHBA is a critical autocrine factor that maintains mesenchymal properties of CICs to promote metastasis in NSCLC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25432175      PMCID: PMC4297542          DOI: 10.1158/0008-5472.CAN-13-2702

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Efficient differentiation of human embryonic stem cells to definitive endoderm.

Authors:  Kevin A D'Amour; Alan D Agulnick; Susan Eliazer; Olivia G Kelly; Evert Kroon; Emmanuel E Baetge
Journal:  Nat Biotechnol       Date:  2005-10-28       Impact factor: 54.908

Review 2.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.

Authors:  Jing Yang; Robert A Weinberg
Journal:  Dev Cell       Date:  2008-06       Impact factor: 12.270

Review 3.  The bright and the dark sides of activin in wound healing and cancer.

Authors:  Maria Antsiferova; Sabine Werner
Journal:  J Cell Sci       Date:  2012-09-18       Impact factor: 5.285

Review 4.  Lung cancer stem cells: tumor biology and clinical implications.

Authors:  Fariz Nurwidya; Akiko Murakami; Fumiyuki Takahashi; Kazuhisa Takahashi
Journal:  Asia Pac J Clin Oncol       Date:  2012-05-21       Impact factor: 2.601

5.  Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells.

Authors:  Lei Xiao; Xuan Yuan; Saul J Sharkis
Journal:  Stem Cells       Date:  2006-02-02       Impact factor: 6.277

6.  Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB.

Authors:  Lin-feng Chen; Yajun Mu; Warner C Greene
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

7.  IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300.

Authors:  Jamie E Hoberg; Anita E Popko; Catherine S Ramsey; Marty W Mayo
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

8.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

Authors:  Haihong Zhong; Michael J May; Eijiro Jimi; Sankar Ghosh
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

9.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

10.  Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.

Authors:  Enza Lonardo; Patrick C Hermann; Maria-Theresa Mueller; Stephan Huber; Anamaria Balic; Irene Miranda-Lorenzo; Sladjana Zagorac; Sonia Alcala; Iker Rodriguez-Arabaolaza; Juan Carlos Ramirez; Raul Torres-Ruíz; Elena Garcia; Manuel Hidalgo; David Álvaro Cebrián; Rainer Heuchel; Matthias Löhr; Frank Berger; Peter Bartenstein; Alexandra Aicher; Christopher Heeschen
Journal:  Cell Stem Cell       Date:  2011-11-04       Impact factor: 24.633

View more
  34 in total

1.  Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

Authors:  Benjamin A Weinberg; Kyle Gowen; Thomas K Lee; Sai-Hong Ignatius Ou; Robert Bristow; Lauren Krill; M Isabel Almira-Suarez; Siraj M Ali; Vincent A Miller; Stephen V Liu; Samuel J Klempner
Journal:  Oncologist       Date:  2017-02-13

Review 2.  Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

3.  Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy.

Authors:  Yusuke Katayama; Takashi Oshima; Kentaro Sakamaki; Toru Aoyama; Tsutomu Sato; Katsuhiko Masudo; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Toshio Imada; Munetaka Masuda
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 4.  Importance of Fibrosis in the Pathogenesis of Uterine Leiomyoma and the Promising Anti-fibrotic Effects of Dipeptidyl Peptidase-4 and Fibroblast Activation Protein Inhibitors in the Treatment of Uterine Leiomyoma.

Authors:  Anusha Shreenidhi Bhat; Ningthoujam Anirudh Singh; Emdormi Rymbai; Swapna Birendra; Saravanan Jayaram; Divakar Selvaraj
Journal:  Reprod Sci       Date:  2022-08-15       Impact factor: 2.924

5.  Low expression of INHB co-receptor TGFBR3 in connection with metastasis and immune infiltration in lung adenocarcinoma.

Authors:  Guoying Zou; Ying Wu; Biqiong Ren; Yuanyuan Wu; Qing Zhu; Junyu He; Zhihong Luo
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

6.  Translational regulation of inhibin βA by TGFβ via the RNA-binding protein hnRNP E1 enhances the invasiveness of epithelial-to-mesenchymal transitioned cells.

Authors:  B V Howley; G S Hussey; L A Link; P H Howe
Journal:  Oncogene       Date:  2015-06-22       Impact factor: 9.867

7.  SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.

Authors:  Leiming Xia; Fan Yang; Xiao Wu; Suzhi Li; Chen Kan; Hong Zheng; Siying Wang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

8.  Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer.

Authors:  Mara De Martino; Camille Daviaud; Julie M Diamond; Jeffrey Kraynak; Amandine Alard; Silvia C Formenti; Lance D Miller; Sandra Demaria; Claire Vanpouille-Box
Journal:  Cancer Immunol Res       Date:  2020-10-22       Impact factor: 12.020

9.  microRNA-211-mediated targeting of the INHBA-TGF-β axis suppresses prostate tumor formation and growth.

Authors:  Zhifeng Zhao; Kai Wang; Shanfeng Tan
Journal:  Cancer Gene Ther       Date:  2020-11-22       Impact factor: 5.854

Review 10.  The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in Cancer Initiation and Progression.

Authors:  Marco Tafani; Luigi Sansone; Federica Limana; Tania Arcangeli; Elena De Santis; Milena Polese; Massimo Fini; Matteo A Russo
Journal:  Oxid Med Cell Longev       Date:  2015-12-20       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.